Veracyte, Inc. (VCYT) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
the bull case· 4
367
managers reporting a position in thirteen f filings
13fJun 30 '269
disclosed supplier and customer ties in sec filings
sec filingsedgar13.00%
of revenue from the largest disclosed customer UnitedHealthcare Group
10-Kfiled Feb 28 '255
of the funds on file reporting a position in VCYT
n-portas of Jun 30 '26the bear case· 3
10 of 24
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '26−0.85%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '260.89%
of ARK Innovation ETF's assets the largest fund weight on file
n-portApr 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 5 '26 report. Not a forecast, not advice.
Of the 6 companies Veracyte, Inc. moves with most closely, 1 also shares its SEC classification.
Measured against 501 trading days of our own closes. Co-movement, not cause.
SIC 8071, Services-Medical Laboratories, from each company's own filings. Largest first.
A rule beside a ticker marks a company that appears in both readings.
Which of these the filings never mention ›Veracyte, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Services-Medical Laboratories
High 40.73 at 10:15 am ET, low 39.70 at 4:00 pm ET.
VCYT (Veracyte, Inc.) has 2 disclosed suppliers and 7 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
367 managers report a position worth $5.2B between them, and 33 of them hold 80% of it.
tall tick = annual report · 2 on record